Skip to main content
. Author manuscript; available in PMC: 2015 Aug 12.
Published in final edited form as: Lancet. 2014 Mar 12;383(9935):2136–2143. doi: 10.1016/S0140-6736(13)62630-6

Table 1.

Baseline characteristics and compliance to administration of vaccine/placebo in enrolled subjects

Number of subjects Vaccine
4532
Placebo
2267
Delhi 2532 1267
Pune 1000 500
Vellore 1000 500
Age in weeks at dosing, Mean (SD)
  Dose 1 6·8 (0·6) 6·8 (0·6)
  Dose 2 11·7 (2·4) 11·7 (2·4)
  Dose 3 16·3 (2·8) 16·4 (2·8)
Gender, n (%)
  Males 2330 (51·4) 1157 (51·0)
Subjects who received each dose, n (%)
  Dose 1 4532 (100·0) 2267 (100·0)
  Dose 2 4409 (97·3) 2221 (98·0)
  Dose 3 4356 (96·1) 2190 (96·6)